Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test - Guardant Health (NASDAQ:GH)

Guardant wins FDA approval for updated liquid biopsy

The company could secure a higher price for the new test than for its older, narrower product, Wall Street analysts said.

Guardant Health Secures FDA Approval For Expanded Liquid Biopsy Test - Guardant Health (NASDAQ:GH)

Guardant Health secured FDA approval for Guardant360 Liquid CDx, expanding blood-based cancer profiling capabilities. Importance Rank:  1

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

PALO ALTO, Calif.--(BUSINESS WIRE)--May 20, 2026-

FDA approves Guardant Health’s next-generation liquid biopsy panel

According to Guardant, Guardant360 Liquid assesses a ‘100x wider’ genomic footprint to guide cancer treatment decisioning than its predecessor.The post FDA approves Guardant Health’s next-generation liquid biopsy panel appeared first on Medical Device Network.